> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# West Pharmaceutical Refinanced $203.0 Million Of 2027 Debt Just Before Its Quarterly Report
- URL: https://www.bullished.co/west-pharmaceutical-refinanced-203-0-million-of-2027-debt-just-before-its-quarterly-report-b5e60343/
- Published: 2026-10-29T20:31:38.000Z
- Updated: 2026-10-29T20:31:38.000Z
- Description: A new $200 million term loan and $750 million revolver run to 2031, as $685.3 million of buybacks cut cash to $464.1 million.
- Author: Matteo Parrino
- Tags: SEC Filings, WST, Industry: Healthcare

[West Pharmaceutical](https://www.bullished.co/tag/wst/)'s [10-Q, filed Thursday](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000121/wst-20260930.htm?ref=bullished.co), carries $203.0 million of 2027 debt as long-term only because a refinancing closed on October 26, before the statements were issued. The maker of containment and delivery systems for injectable drugs has also spent $685.3 million on buybacks in the first nine months of 2026.

## Two 2027 maturities, one new facility

The old debt was a $130.0 million term loan due July 2, 2027, and $73.0 million of 4.02% Series C notes due July 5, 2027\. The [prior quarter's 10-Q](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000099/wst-20260630.htm?ref=bullished.co) showed the same two maturities alongside a $500.0 million revolver.

The new agreement, with Bank of America as administrative agent, [matures October 26, 2031](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/wst-20261026.htm?ref=bullished.co). It pairs a $750 million revolver with a $200 million term loan, which replaced the $130.0 million loan. Quarterly term-loan payments of $1.25 million to $2.5 million start March 31, 2028.

The $73.0 million of Series C notes is slated for repayment on or about November 2, 2026, partly from the new loan. No make-whole premium applies. A leverage covenant caps net leverage at 3.50 to 1.0, rising for big acquisitions. The 8-K says proceeds may fund acquisitions and stock repurchases.

## Buybacks drain the cash pile

West bought 2,424,121 shares for $685.3 million over nine months, an average $282.68 a share. Third-quarter buying was [$231.0 million](https://seekingalpha.com/news/4659985-west-pharmaceutical-beats-top-line-and-bottom-line-estimates-raises-fy26-outlook?ref=bullished.co), or 663,511 shares, at an average $348.11\. A new $1.0 billion authorization approved in February has no expiration date.

Cash fell to $464.1 million at September 30 from $791.3 million at year-end. Operating cash flow for the nine months was $403.4 million, down from $503.7 million a year earlier. Accounts receivable climbed to $748.2 million from $574.4 million, which the company ties to the timing of sales and customer collections.

The stock closed Thursday with a market value of $28.4 billion.

## Sales and profit still growing

Third-quarter [net sales rose 8.7%](https://www.cnbc.com/2026/10/29/west-pharma-earnings-growth-beyond-glp-1.html?ref=bullished.co) to $874.5 million, or 11.9% organically, and diluted earnings per share were $3.02\. Proprietary Products, which sells mainly to drug companies, grew 12.6%, led by high-value components. West Vantage, the contract-manufacturing unit, fell 7.3%.

A $55.7 million gain on selling the SmartDose 3.5mL delivery system to AbbVie flattered the quarter's profit, and adjusted EPS was $2.66\. The [earnings release](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/exh991q32026earningsrelease.htm?ref=bullished.co) raised full-year net sales guidance to $3.41 billion to $3.42 billion and adjusted EPS guidance to $9.38 to $9.48.

The Series C repayment is due on or about November 2, 2026, and the new term loan's first payment follows on March 31, 2028.

### Sources

- [10-Q Filing — West Pharmaceutical (WST)](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000121/wst-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — West Pharmaceutical (WST), Q2 FY2026 filed 2026-07-23 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000099/wst-20260630.htm?ref=bullished.co) — SEC EDGAR
- [8-K Filing — West Pharmaceutical, filed 2026-10-26 (Items 1.01, 1.02, 2.03, 9.01)](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000114/wst-20261026.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, exh991q32026earningsrelease.htm) — West Pharmaceutical, filed 2026-10-29](https://www.sec.gov/Archives/edgar/data/0000105770/000010577026000118/exh991q32026earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [West Pharma earnings show why it's more than a GLP-1 play](https://www.cnbc.com/2026/10/29/west-pharma-earnings-growth-beyond-glp-1.html?ref=bullished.co) — CNBC
- [West Pharmaceutical Earnings: High-Quality Growth and Margin Support Another Guidance Raise](https://www.morningstar.com/company-reports/1505967-west-pharmaceutical-earnings-high-quality-growth-and-margin-support-another-guidance-raise?listing=0P000005WS&ref=bullished.co) — morningstar.com
- [Compared to Estimates, West Pharmaceutical (WST) Q3 Earnings: A Look at Key Metrics](https://finance.yahoo.com/markets/stocks/articles/compared-estimates-west-pharmaceutical-wst-123006251.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [West Pharmaceutical beats top-line and bottom-line estimates; raises FY26 outlook | Seeking Alpha](https://seekingalpha.com/news/4659985-west-pharmaceutical-beats-top-line-and-bottom-line-estimates-raises-fy26-outlook?ref=bullished.co) — seekingalpha.com
- [WST Q3 Earnings Preview: Will HVP Strength Offset Vantage Weakness?](https://finance.yahoo.com/healthcare/articles/wst-q3-earnings-preview-hvp-123900035.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance

### More on West Pharmaceutical

- [West Pharmaceutical Stock Surges 7%, Adding $1.9 Billion, As Company Lifts 2026 Outlook](https://www.bullished.co/west-pharmaceutical-stock-surges-7-adding-1-9-billion-as-company-lifts-2026-outlook-f0c470fb/)
- [West Pharmaceutical Says GLP-1 Surge Had 'Nothing One-Offish' — But Margins Are Not 'The New Floor'](https://www.bullished.co/west-pharmaceutical-says-glp-1-surge-had-nothing-one-offish-but-margins-are-not-the-new-6401a116/)
- [West Pharmaceutical's New CEO Says The Bar For Acquisitions Is 'Incredibly High' As Customers Cut Supplier Lists](https://www.bullished.co/west-pharmaceuticals-new-ceo-says-the-bar-for-acquisitions-is-incredibly-high-as-customers-6faf3bb0/)

[All West Pharmaceutical (WST) coverage →](https://www.bullished.co/tag/wst/)